Imaging of response to treatment in oncology

被引:13
作者
Fournier, L. S. [1 ]
Cuenod, C. A. [1 ]
Clement, O. [1 ]
Siauve, N. [1 ]
Frija, G. [1 ]
机构
[1] Hop Europeen Georges Pompidou, Serv Radiol, F-75015 Paris, France
来源
JOURNAL DE RADIOLOGIE | 2007年 / 88卷 / 06期
关键词
cancer; imaging functional; therapy response; RECIST; RENAL-CELL CARCINOMA; SOLID TUMORS; NEOADJUVANT CHEMOTHERAPY; IN-VIVO; CANCER; DIFFUSION; THERAPY; PROSTATE; CRITERIA; RECIST;
D O I
10.1016/S0221-0363(07)89885-4
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Imaging plays a crucial role in oncology to assist in the management of patients and selection of drug regimen. Recent advances in imaging techniques allowing to predict and evaluate response to treatments in oncology will be reviewed. The standard in the evaluation of response to treatment is based on the measurement of lesion size. Functional imaging assesses physiological or molecular processes that may be earlier indicators of early response to treatment. Dynamic imaging of tumor vascularization assesses the biodistribution of a contrast agent within tumoral tissues. Diffusion-weighted MR imaging can differentiate free water from water restricted by tissues, providing an assessment of tumor cellularity. MR spectroscopy assesses the relative quantity of specific chemical components within normal and tumoral tissues. 18 FDG PET imaging provides an assessment of the metabolic activity of tissues. FDG uptake is proportional to cellular proliferation and number of viable cells within a tumor. Results from studies assessing the role of these emerging imaging techniques remain preliminary and the medical community must determine their respective role in the routine evaluation of response to treatment in oncological patients.
引用
收藏
页码:829 / 843
页数:15
相关论文
共 34 条
  • [1] Kinase inhibition with BAY 43-9006 n renal cell carcinoma
    Ahmad, T
    Eisen, T
    [J]. CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6388S - 6392S
  • [2] Neovastat (Æ-941) in refractory renal cell carcinoma patients:: report of a phase II trial with two dose levels
    Batist, G
    Patenaude, F
    Champagne, P
    Croteau, D
    Levinton, C
    Hariton, C
    Escudier, B
    Dupont, E
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (08) : 1259 - 1263
  • [3] Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma
    De Bazelaire, C
    Rofsky, NM
    Duhamel, G
    Michaelson, MD
    George, D
    Alsop, DC
    [J]. ACADEMIC RADIOLOGY, 2005, 12 (03) : 347 - 357
  • [4] Duffaud F, 2000, B CANCER, V87, P881, DOI 10.1093/jnci/92.3.205
  • [5] Human rectal adenocarcinoma:: Demonstration of 1H-MR spectra in vivo at 1.5 T
    Dzik-Jurasz, ASK
    Murphy, PS
    George, M
    Prock, T
    Collins, DJ
    Swift, I
    Leach, MO
    Rowland, IJ
    [J]. MAGNETIC RESONANCE IN MEDICINE, 2002, 47 (04) : 809 - 811
  • [6] Evaluation of tumor angiogenesis with US: Imaging, Doppler, and contrast agents
    Ferrara, KW
    Merritt, CRB
    Burns, PN
    Foster, FS
    Mattrey, RF
    Wickline, SA
    [J]. ACADEMIC RADIOLOGY, 2000, 7 (10) : 824 - 839
  • [7] FOURNIER LS, IN PRESS SERIES MRI
  • [8] MR spectroscopy of brain tumors.
    Galanaud, D.
    Nicoli, F.
    Figarella-Branger, D.
    Roche, P.
    Confort-Gouny, S.
    Le Fur, Y.
    Cozzone, P. J.
    [J]. JOURNAL DE RADIOLOGIE, 2006, 87 (06): : 822 - 832
  • [9] Measuring response in solid tumors: Unidimensional versus bidimensional measurement
    James, K
    Eisenhauer, E
    Christian, M
    Terenziani, M
    Vena, D
    Muldal, A
    Therasse, P
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (06) : 523 - 528
  • [10] Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.1-cm(3)) spatial resolution
    Kurhanewicz, J
    Vigneron, DB
    Hricak, H
    Narayan, P
    Carroll, P
    Nelson, SJ
    [J]. RADIOLOGY, 1996, 198 (03) : 795 - 805